NUEVAS NOCIONES ACERCA DE LOS ANTAGONISTAS DE LOS RECEPTORES GPIIB/GPIIIA
Columnista Experto de SIIC Dermot Cox
en colaboración con
Primera edición en siicsalud:
19 de septiembre, 2003
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/20051
Especialidad principal:
Farmacología
Especialidades relacionadas:
Cardiología,Medicina Farmacéutica,Medicina Interna,
Helicobacter pylori interacts with GPIb to induce platelet aggregation, Gastroenterology :
Characterization of a ligand-attenuated binding site on glycoprotein IIb/IIIa, Thrombosis & Haemostasis 88(88):811-816, 2002
A role for Glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation, Blood 100:509-516, 2002
Staphylococcus aureus-induced platelet aggregation involves clumping factors A and B and the serine-aspartate repeat protein E., Molecular Microbiology 44(44):1033-1044, 2002
Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist, Journal Pharmacology Experimental Therapeutics 295(295):670-676, 2000
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes, Journal American College of Cardiology 36(36):1514-1519, 2000
Quantifying GPIIb/IIIa receptor binding using two monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists, Circulation 99(99):, 1999
Dermot Cox
